The Total Return for Shenzhen Mindray Bio-Medical Electronics (SZSE:300760) Investors Has Risen Faster Than Earnings Growth Over the Last Five Years
The Total Return for Shenzhen Mindray Bio-Medical Electronics (SZSE:300760) Investors Has Risen Faster Than Earnings Growth Over the Last Five Years
Generally speaking the aim of active stock picking is to find companies that provide returns that are superior to the market average. And the truth is, you can make significant gains if you buy good quality businesses at the right price. For example, the Shenzhen Mindray Bio-Medical Electronics Co., Ltd. (SZSE:300760) share price is up 43% in the last 5 years, clearly besting the market return of around 15% (ignoring dividends).
一般來說,積極選股的目的是找到能夠提供超過市場平均回報的公司。 實際上,如果你以合適的價格購買優質的業務,可以獲得顯著的收益。例如,邁瑞醫療(SZSE:300760)在過去五年中的股價上漲了43%,明顯超過了市場大約15%的回報(不考慮分紅派息)。
In light of the stock dropping 3.4% in the past week, we want to investigate the longer term story, and see if fundamentals have been the driver of the company's positive five-year return.
鑑於股票在過去一週下跌了3.4%,我們希望調查更長期的故事,看看基本面是否推動了公司積極的五年回報。
While the efficient markets hypothesis continues to be taught by some, it has been proven that markets are over-reactive dynamic systems, and investors are not always rational. By comparing earnings per share (EPS) and share price changes over time, we can get a feel for how investor attitudes to a company have morphed over time.
儘管有效市場假說仍然被一些人教授,但已經證明市場是一種反應過度的動態系統,投資者並不總是理性。通過比較每股收益(EPS)和股價變化,我們可以感受到投資者對公司的態度在一段時間內是如何變化的。
During five years of share price growth, Shenzhen Mindray Bio-Medical Electronics achieved compound earnings per share (EPS) growth of 22% per year. This EPS growth is higher than the 7% average annual increase in the share price. So it seems the market isn't so enthusiastic about the stock these days.
在五年的股價增長中,邁瑞醫療實現了每股收益(EPS)年均增長22%。 這個EPS增長高於股價年均增長7%的平均水平。因此,看起來市場對這隻股票最近並不是那麼熱情。
You can see how EPS has changed over time in the image below (click on the chart to see the exact values).
您可以在下面的圖像中查看每股收益隨時間的變化(單擊圖表查看確切值)。
Before buying or selling a stock, we always recommend a close examination of historic growth trends, available here.
在買入或賣出股票之前,我們總是建議仔細審查歷史增長趨勢,詳情請見這裏。
What About Dividends?
關於分紅派息的問題
It is important to consider the total shareholder return, as well as the share price return, for any given stock. The TSR incorporates the value of any spin-offs or discounted capital raisings, along with any dividends, based on the assumption that the dividends are reinvested. So for companies that pay a generous dividend, the TSR is often a lot higher than the share price return. We note that for Shenzhen Mindray Bio-Medical Electronics the TSR over the last 5 years was 54%, which is better than the share price return mentioned above. This is largely a result of its dividend payments!
在評估任意股票時,考慮總股東回報以及股價回報非常重要。總股東回報考慮了任何分拆或折扣融資的價值,以及任何分紅派息,假設這些分紅派息被再投資。因此,對於支付慷慨分紅的公司,總股東回報通常遠高於股價回報。我們注意到,邁瑞醫療在過去5年中的總股東回報爲54%,這優於上述提到的股價回報。這主要是由於其分紅派息所致!
A Different Perspective
不同的視角
While the broader market gained around 14% in the last year, Shenzhen Mindray Bio-Medical Electronics shareholders lost 11% (even including dividends). Even the share prices of good stocks drop sometimes, but we want to see improvements in the fundamental metrics of a business, before getting too interested. On the bright side, long term shareholders have made money, with a gain of 9% per year over half a decade. If the fundamental data continues to indicate long term sustainable growth, the current sell-off could be an opportunity worth considering. It's always interesting to track share price performance over the longer term. But to understand Shenzhen Mindray Bio-Medical Electronics better, we need to consider many other factors. To that end, you should be aware of the 1 warning sign we've spotted with Shenzhen Mindray Bio-Medical Electronics .
雖然整體市場在過去一年中上漲了約14%,但邁瑞醫療的股東卻損失了11%(即使包括分紅派息)。即使是好的股票,其股價有時也會下跌,但在對基本指標感興趣之前,我們希望看到企業的改善。好消息是,長期股東已經獲利,過去半個十年每年增長了9%。如果基本數據繼續顯示長期可持續增長,當前的賣出可能是一個值得考慮的機會。跟蹤長期的股價表現總是很有趣。但爲了更好地理解邁瑞醫療,我們需要考慮許多其他因素。爲此,你應該注意到我們發現的一個關於邁瑞醫療的警告信號。
Of course Shenzhen Mindray Bio-Medical Electronics may not be the best stock to buy. So you may wish to see this free collection of growth stocks.
當然,邁瑞醫療可能不是最適合買入的股票。所以你可能想看看這份免費的成長股票合集。
Please note, the market returns quoted in this article reflect the market weighted average returns of stocks that currently trade on Chinese exchanges.
請注意,本文中引用的市場回報反映了目前在中國交易所交易的股票的市場加權平均回報。
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
對本文有反饋?對內容有疑慮?請直接與我們聯繫。或者,發送電子郵件至 editorial-team (at) simplywallst.com。
這篇來自Simply Wall ST的文章是一般性的。我們根據歷史數據和分析師預測提供評論,採用無偏見的方法,我們的文章並不旨在提供財務建議。它不構成對任何股票的買入或賣出建議,也未考慮到您的目標或財務狀況。我們旨在爲您提供以基本數據驅動的長期分析。請注意,我們的分析可能未考慮最新的價格敏感公司公告或定性材料。Simply Wall ST在提到的任何股票中均沒有持倉。